Following qualification of targets in this cancer-related pathway, a functional cellular assay was used to analyze the potential therapeutic benefit of combining RNAi and kinase inhibitors against EGFR and MEK-1 in the AP-1 activation pathway of a human cervical cancer cell line. Here, EGFR is linked to cervical cancer.